Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for September 2011
September 1, 2011
- New Data from Bristol-Myers Squibb on NULOJIX (belatacept) to be Presented at the 2011 European Society for Organ Transplantation Congress
- Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
- AF AWARE: New Doctors' Tool to Tackle Rising Atrial Fibrillation Threat
- Toshiba's New Kalare Imaging System Receives FDA Clearance
- Vexim, the Specialist in Minimally Invasive Anatomical Restoration of Vertebral Compression Fractures, Announces the CE Marking and the Market Launch of Its New 6.5 mm Diameter SpineJack Implant
- Vimpat (lacosamide) provided sustained efficacy and good tolerability for up to 8 years in patients with partial onset seizures
September 2, 2011
- Medical Marijuana Inc. Patent Pending Extraction ---- Cannabidiol (CBD) Possible Use In The Anti-Tumor and Anti-Cancer Nutraceutical and Pharmaceutical Industries
- AstraZeneca Announces Top-Line Results From SATURN Study
- Persistent Immunity: Wistar Researchers Find Signals that Preserve the Production of Anti-Viral Antibodies
- McMaster Study Finds More Gut Reaction to Arthritis Drugs
- Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
- Study: U.S. Newborn Death Rate on Par with Qatar and Croatia, Worse Than in 40 Countries ? Including S. Korea, Cuba, Poland
- New Data on Long-Term Use of FIRMAGON (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology
September 6, 2011
- Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1
- BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
- Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis
- AiCuris: No Resistant Herpes Simplex Virus (HSV) Observed in Phase II Trial with Herpes Drug AIC316
- Valdoxan (Agomelatine): New Evidence Shows Significant Efficacy in Treatment of Anxiety in Depressed Patients
- Jennerex Presents Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer
- Medical Marijuana Inc.'s Marijuana Extract Cannabidiol (CBD) Possible Use As A Prevention And Treatment To Alzheimer's Disease
- BioAlliance Pharma: Presentation of Livatag Survival Results at the International Liver Cancer Congress in Hong Kong
- New Tactic for Controlling Blood Sugar in Diabetes Contradicts Current View of the Disease
- 4SC's Resminostat Meets Primary Efficacy Endpoint in Phase II Trial in Hodgkin's Lymphoma (HL)
- OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
- Veloxis Pharmaceuticals' Once-Daily LCP-Tacro Meets Non-Inferiority Endpoint When Compared to Twice-Daily Tacrolimus Tablets in Stable Kidney Transplant Patients
- Furiex Reports Positive Phase II Results for MuDelta in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
- Therapeutic Dosing of Synthetic Antimi Further Demonstrates the Potential of microRNA-208 Inhibition in Treatment of Chronic Heart Failure
September 7, 2011
- TONIX Pharmaceuticals' Bedtime Very Low Dose Cyclobenzaprine Study Featured in Journal of Rheumatology
- Syndax Pharmaceutical's Positive Phase 2 Data Supports Potential for Entinostat in Advanced Breast Cancer
- biocrea?s first-in-class PDE2 inhibitor demonstrates strong potential for the treatment of cognitive disorders
- Teva and Alcobra Announce Phase II Trial of Novel, Non-Stimulant MG01CI for ADHD Meets Primary Endpoint
- Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX Multi-Cord Study
September 8, 2011
September 9, 2011
- Lapatinib clinical trial update
- SPX-106T Treatment Yields Significant Reductions in Serum VLDL and LDL Cholesterol in Mice
September 12, 2011
- More Patients with Type 2 Diabetes Reach HbA[1c] Target with Apidra on top of Lantus Than with Twice-daily Aspart Premixed Insulin
- New Research Indicates Treating Neonatal Respiratory Distress Syndrome with CUROSURF® Results in Lower Rate of Mortality Compared to Competitive Surfactants
- BioSante Pharmaceuticals Successfully Completes LibiGel Pharmacokinetic Study
- Alnylam Scientists and Collaborators Report Significant New Advances in Delivery of RNAi Therapeutics at 2011 Oligonucleotides Therapeutics Society Meeting
- Lyxumia (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes
- Cardiorenal Actions of Trevena Biased Ligand Heart Failure Drug Explained in Mayo Clinic Publication and Presentations
September 13, 2011
- LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
- Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraCol for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
- Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology
- BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain
- Lyxumia (lixisenatide) one-step treatment regimen as effective as two-step regimen in improving glycemic control in type 2 diabetes
- Inovio Pharmaceuticals' PENNVAX-G Global HIV Vaccine Plus MVA Boost Achieves 100% Antigen-Specific T-Cell Immune Responses in Interim Phase I Data
- Medical Marijuana Inc. Marijuana Extract Cannabidiol (CBD) Shows Therapeutic Benefit For Multiple Sclerosis (MS)
- Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
- Study Finds No Association Between Intracerebral Hemorrhage and Use of Statins Among Patients With Prior Stroke
- Nasal Insulin Spray Shows Promise In Treatment of Alzheimer's
- NCCN Expert Discusses Extending Life-Saving Pediatric Treatments to Adults with Acute Lymphoblastic Leukemia
- Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery
- Inovio Pharmaceuticals? PENNVAX?-G Global HIV Vaccine Plus MVA Boost Achieves 100% Antigen-Specific T-Cell Immune Responses in Interim Phase I Data
- BioAlliance Pharma announces positive preliminary phase I clinical results with its AMEP biotherapy for metastatic melanoma
September 14, 2011
- Aeterna Zentaris Presents Positive Final Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ESGO Meeting in Milan, Italy
- Nuvo Research provides update on the PENNSAID Viscous Solution development program
- Combination treatment suggests a comprehensive effect on patients with Alzheimer's disease (AD) - latest study results presented at EFNS
- Inovio Pharmaceuticals Completes PENNVAX-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
- Novartis Drug Galvus Shown to Be Well-Tolerated and Effective in Patients With Type 2 Diabetes and Moderate Or Severe Renal Impairment
- Tekmira and Collaborators Demonstrate Efficacy of RNAi Against Hepatitis C Virus
- NCCN Guidelines Emphasize Patient Preference as Key to Selection of Maintenance Therapy in Follicular Lymphoma
- Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
- Phase 2 Study of Eculizumab (Soliris) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting
- New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK(telaprevir) in Hepatitis C
- University of Maryland School of Medicine Scientists Identify First Effective Blood-Stage Malaria Vaccine
September 15, 2011
- Syndax Pharmaceutical?s Positive Phase 2 Data Supports Potential for Entinostat in Advanced Breast Cancer
- Novel Formulation of Diclofenac Provides Pain Relief at Lower Doses
- Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec Study in Acute GI GVHD
- Novel anthrax vaccine and antitoxin being developed with federal support
- ChemoCentryx Reports CCX140-B Meets Primary Endpoint and Demonstrates Clinical Efficacy in Phase II Study in Type 2 Diabetes
- DARA BioSciences Selected to Present the Positive Results of KRN5500 Phase 2 Study at the 5th Annual Therapeutics Summit
September 16, 2011
- ONGLYZA (saxagliptin) When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels (HbA1c) Over 52 Weeks in Investigational Study Extension
- Intercell and Biological E. Ltd. announce successful completion of investigational Japanese Encephalitis vaccine pivotal Phase II/III study in India
- Novartis study showed ACZ885 provided substantial symptom relief in 84% of patients with the most serious form of childhood arthritis
- Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
- Chimerix Announces Late-Breaker Presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
- NPS Pharmaceuticals Highlights Hypoparathyroidism Data to be Presented at Annual Meeting of American Society for Bone and Mineral Research
September 19, 2011
- BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients
- Merck's ISENTRESS (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race
September 20, 2011
- Glycotope Enrolls First Patients in Phase I Trial with TrasGEX, a Glycooptimized HER2 Biobetter Antibody
- Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
- Active Biotech's Prostate Cancer Project TASQ Featured in Journal of Clinical Oncology
- Data to be presented at ERS 2011 reinforce benefit of Daxas® (roflumilast) as a treatment to target COPD inflammation
- Gilead's Second Pivotal Phase 3 Clinical Study of the Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective
- SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
- New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs presented at ICAAC
- NicOx presents new preclinical data for NCX 6560
- Research Suggests FORTEO Significantly Increases Bone Strength
- Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781
- TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients
- New Data on Odanacatib, Merck's Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research
- Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
- Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta
- Rib-X Pharmaceuticals Presents Comprehensive Overview of RX-04 Program in 14 Posters at ICAAC
- Over 5 Million Children are Currently Treated with ADHD Medication; Study Shows a Majority May Be Unnecessarily Medicated
- Santarus Announces Supportive Top-Line Results from Budesonide MMX Extended Use Study
- Continued Treatment For Lupus May Boost Survival of Those Patients with End-Stage Kidney Disease
- Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
September 21, 2011
- Aradigm Presents Additional Analyses of the Clinical Results From ORBIT-1 and ORBIT-2 Trials of Inhaled Ciprofloxacin at the 2011 European Respiratory Society (ERS) Annual Congress
- American Pain Foundation Survey Uncovers Treatment Questions and Concerns Among People with Pain
September 22, 2011
- 12-Month Maintenance Data Affirms Benefit of Adding L-Methylfolate With An Antidepressant for Relapse Prevention
- Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting
- New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia
- Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease)
- Pulmatrix to Present Data on PUR118 for Respiratory Diseases at European Respiratory Society Congress
September 23, 2011
- European CHMP Adopts Positive Opinion for Eviplera, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection
- Regeneron Announces ZALTRAP Clinical Presentation at European Multidisciplinary Cancer Congress
- Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID
- ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma
- Novartis Gains Positive CHMP Opinion for Rasitrio, First Rasilez-Based Triple Combination Pill in Europe to Treat High Blood Pressure
- Edurant (rilpivirine) Receives Positive Opinion From the Committee for Medicinal Products for Human Use (CHMP) for Use in Treatment-Naive Adults with HIV-1
- European Medicines Agency Recommends Authorisation of Novel Antibiotic Agent
- Alexion Receives CHMP Positive Opinion for Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European Union
- CHMP Post-Authorisation Summary of Opinion for Alimta (II-33)
- Novartis Drug Afinitor Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
- Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
September 26, 2011
- Novartis Drug Afinitor Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
- Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
- New Data Demonstrate Longer-Term Safety Profile of Esbriet
- Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma
- Topiramate Exposure and Fetal Outcomes in Migraine Patients to Be Presented at the 136th ANA Annual Meeting
- Aeterna Zentaris Announces Interim Data for its Phase 1/2 Trial with AEZS-108 in Prostate Cancer at ESMO Congress - AEZS-108 well tolerated at all dose levels / Early evidence of anti-tumor activity
- ARIAD Announces Long-Term Follow Up of Patients with Drug-Resistant CML Treated with Ponatinib in Phase 1 Trial
- Study of Zolinza (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet Primary Endpoint
- Synta Announces Presentation of Results of Ganetespib Study in Combination with Docetaxel in Solid Tumors
- Newly Identified DNA Repair Defect Linked to Increased Risk of Leukemia Relapse
- Regulatory Update: GlaxoSmithKline Receives Complete Response Letter from FDA for candidate meningococcal and Hib combination vaccine
- Upsher-Smith Laboratories Presents Extended-Release Topiramate Data (USL255) at ANA Meeting
- ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
- Pearl Therapeutics' Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva
- Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
- Constellation Pharmaceuticals Announces Publication Demonstrating Pharmacological Suppression of Key Cancer-causing Gene
- Report Finds DMARDs Effective in Treating Juvenile Arthritis
- Encore Therapeutics Inc. Announces Extended Release Depot Formulation of Ropivacaine Available for License
September 27, 2011
- BioLineRx to Present Data from the Successfully Completed Phase IIb Trial of BL-1020 at European Conference on Schizophrenia Research
- Biodel Reports Top-Line Results From Pump Study of Experimental Insulins
- Pulmatrix's PUR118 Demonstrates Potential to Reduce Acute Exacerbations of the Lung Associated with Progressive Respiratory Diseases, such as COPD, Asthma, CF, and Respiratory Infections
- Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
- Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
- Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
- Transition Therapeutics Announces Publication of ELND005 Phase 2 Clinical Study Data in Alzheimer's Disease
- Edurant (Rilpivirine) Receives Positive Opinion From the Committee for Medicinal Products for Human Use (CHMP) for Use in Treatment-Naïve Adults With HIV-1
- Circassia?s Hay Fever Treatment Improves Patients? Allergy Symptoms in Phase II Clinical Trial
- New Novartis Data Show Potential of Respiratory Portfolio to Help COPD Patients Maintain Active and Productive Lives
- Biofrontera delivers final documents for processing the last open issues in the drug application of BF-200 ALA
- Shire Provides Update on ProAmatine (midodrine HCl)
- Youth with Diabetes More Likely to Have Asthma
September 28, 2011
- Chelsea Therapeutics Submits New Drug Application for Northera (droxidopa) for the Treatment of Symptomatic NOH
- Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial
- Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe
- Positive Results for V158866 in Phase I Study
- Nih Modifies 'Voice' Hiv Prevention Study in Women Oral Tenofovir Discontinued in Clinical Trial
- MolMed presents new data from four clinical trials on NGR-hTNF at European Multidisciplinary Cancer Congress
- Pulmatrix?s PUR118 Demonstrates Potential to Reduce Acute Exacerbations of the Lung Associated with Progressive Respiratory Diseases, such as COPD, Asthma, CF, and Respiratory Infections
- COPD patients experienced benefits from the first dose when treated with aclidinium, as shown in the ATTAIN Phase III study
- BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
September 29, 2011
- Almirall Announces Regulatory Filing of linaclotide for the Treatment of Irritable Bowel Syndrome With Constipation in Europe
- Transcept Pharmaceuticals Resubmits Intermezzo NDA to FDA
- Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference
- Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
- Pronova and Takeda Announce the Submission of a New Drug Application for TAK-085 in Japan
- Orexigen Therapeutics Announces Multiple Contrave Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
- Unexpected Link Between Cancer and Diabetes Revealed
- Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
September 30, 2011
- Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis
- Ironwood Announces Linaclotide European Regulatory Submission for the Treatment of Irritable Bowel Syndrome with Constipation
- Topline Results: A Randomized Phase 2 Study of Selumetinib in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
- Baxter Submits European Marketing Authorization Application For HyQ, an Investigational IG Therapy for Primary Immunodeficiencies
- Results of the Pharmaceutical Affairs Subcommittee Regarding the Application of Epogin for Chemotherapy-Induced Anemia
- Bayer AG: Phase III Study of Bayer?s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint
